Janux shares rise on global cancer drug deal with Bristol Myers

Bristol-Myers Squibb Co

22/01/2026 12:35

** Shares of drug developer Janux Therapeutics JANX.O rise 17.33% to $15.57 premarket

**  Co says it signed a global licensing deal with Bristol Myers BMY.N to develop a new solid-tumor cancer drug

**  Co says it may receive up to $50 mln upfront and near-term milestones, plus as much as $800 mln more tied to progress and sales

**  Royalties to follow if the drug is approved and sold, co says

** The drug targets a protein seen across several cancers; per co

**  JANX will handle early research before BMY takes over development and global sales

** Shares down ~74% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))